代谢挑战者选择瘤持久细胞
Caterina Mancini1, Giulia Lori1, Erica Pranzini2
1Department of Experimental and Clinical Medicine, University of Florence, Viale Morgagni 50, 50134 Florence, Italy.
Trends in endocrinology and metabolism: TEM
|December 9, 2023
概括
癌症的耐药性是癌症的一个主要障碍. 瘤微环境 (TME) 通过代谢和表观遗传变化驱动瘤异质性和耐药瘤持久细胞 (TPC) 的进化.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 瘤微环境研究 研究
背景情况:
- 抗癌疗法耐药性仍然是癌症治疗中的一个关键挑战.
- 瘤微环境 (TME) 显著影响药物耐药性的发展.
- 瘤异质性 (TH) 和表观遗传适应是获得耐药性的关键因素.
研究的目的:
- 探索TME代谢压力,表观遗传学和瘤持久细胞 (TPC) 进化之间的联系.
- 了解TPC如何通过表型和代谢可塑性获得抗性优势.
- 通过利用TPC漏洞来确定克服耐药性的新疗法目标.
主要方法:
- 对瘤微环境组件的分析.
- 研究瘤细胞中的表观遗传修饰.
- 瘤持久细胞 (TPC) 的可塑性和新陈代谢的表征.
- 代谢压力与TPC演变和耐药性的相关性.
主要成果:
- TME促进了瘤异质性和耐药克隆的出现.
- 在TME内的代谢压力促进瘤细胞的表观遗传适应.
- 瘤持久细胞 (TPC) 具有显著的表型和代谢可塑性,赋予了化疗和放射性耐药性.
结论:
- 了解TME代谢,表观遗传学和TPC进化之间的相互作用至关重要.
- 针对TPC漏洞是一个有希望的策略,以克服抗癌疗法耐药性.
- 通过专注于TPCs的代谢和表观遗传可塑性,可以开发新的治疗方法.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


